Annual CFF
$187.96 M
+$45.75 M+32.17%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual cash flow from financing activities is currently $187.96 million, with the most recent change of +$45.75 million (+32.17%) on 31 December 2023. During the last 3 years, it has risen by +$335.60 million (+227.31%). LXRX annual CFF is now -33.77% below its all-time high of $283.81 million, reached on 31 December 2014.LXRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$916.00 K
-$902.00 K-6442.86%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly cash flow from financing activities is currently -$916.00 thousand, with the most recent change of -$902.00 thousand (-6442.86%) on 30 September 2024. Over the past year, it has dropped by -$706.00 thousand (-336.19%). LXRX quarterly CFF is now -100.32% below its all-time high of $285.67 million, reached on 31 December 2014.LXRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$238.45 M
-$706.00 K-0.30%
30 September 2024
Summary:
Lexicon Pharmaceuticals TTM cash flow from financing activities is currently $238.45 million, with the most recent change of -$706.00 thousand (-0.30%) on 30 September 2024. Over the past year, it has increased by +$25.59 million (+12.02%). LXRX TTM CFF is now -44.31% below its all-time high of $428.17 million, reached on 31 March 2024.LXRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +32.2% | -336.2% | +12.0% |
| 3 y3 years | +227.3% | -104.6% | +142.9% |
| 5 y5 years | +8476.1% | -186.3% | +10000.0% |
LXRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +227.3% | -100.4% | +91.9% | -44.3% | +950.0% |
| 5 y | 5 years | at high | +227.3% | -100.4% | +99.6% | -44.3% | +212.4% |
| alltime | all time | -33.8% | +227.3% | -100.3% | +99.6% | -44.3% | +212.4% |
Lexicon Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$916.00 K(+6442.9%) | $238.45 M(-0.3%) |
| June 2024 | - | -$14.00 K(-100.0%) | $239.16 M(-44.1%) |
| Mar 2024 | - | $239.38 M(<-9900.0%) | $428.17 M(+127.8%) |
| Dec 2023 | $187.96 M(+32.2%) | -$1000.00(-99.5%) | $187.96 M(-11.7%) |
| Sept 2023 | - | -$210.00 K(-100.1%) | $212.87 M(-30.7%) |
| June 2023 | - | $189.00 M(<-9900.0%) | $307.10 M(+160.0%) |
| Mar 2023 | - | -$824.00 K(-103.3%) | $118.10 M(-17.0%) |
| Dec 2022 | $142.21 M(+526.2%) | $24.91 M(-73.5%) | $142.21 M(+34.2%) |
| Sept 2022 | - | $94.02 M(>+9900.0%) | $105.98 M(+233.9%) |
| June 2022 | - | $0.00(-100.0%) | $31.74 M(+0.1%) |
| Mar 2022 | - | $23.28 M(-305.7%) | $31.72 M(+39.7%) |
| Dec 2021 | $22.71 M(-115.4%) | -$11.32 M(-157.2%) | $22.71 M(-76.9%) |
| Sept 2021 | - | $19.78 M(<-9900.0%) | $98.18 M(-174.5%) |
| June 2021 | - | -$23.00 K(-100.2%) | -$131.72 M(-0.3%) |
| Mar 2021 | - | $14.27 M(-77.8%) | -$132.12 M(-10.5%) |
| Dec 2020 | -$147.64 M(+6532.3%) | $64.15 M(-130.5%) | -$147.64 M(-30.4%) |
| Sept 2020 | - | -$210.12 M(>+9900.0%) | -$212.11 M(+9078.2%) |
| June 2020 | - | -$425.00 K(-65.8%) | -$2.31 M(+4.7%) |
| Mar 2020 | - | -$1.24 M(+286.3%) | -$2.21 M(-0.8%) |
| Dec 2019 | -$2.23 M(-0.8%) | -$322.00 K(+0.6%) | -$2.23 M(+9.0%) |
| Sept 2019 | - | -$320.00 K(-0.6%) | -$2.04 M(-1.7%) |
| June 2019 | - | -$322.00 K(-74.5%) | -$2.08 M(+5.1%) |
| Mar 2019 | - | -$1.26 M(+807.9%) | -$1.98 M(-11.9%) |
| Dec 2018 | -$2.24 M(-101.5%) | -$139.00 K(-61.0%) | -$2.24 M(-101.5%) |
| Sept 2018 | - | -$356.00 K(+61.1%) | $145.74 M(+0.1%) |
| June 2018 | - | -$221.00 K(-85.5%) | $145.60 M(-2.6%) |
| Mar 2018 | - | -$1.53 M(-101.0%) | $149.51 M(-0.3%) |
| Dec 2017 | $149.93 M(>+9900.0%) | $147.84 M(<-9900.0%) | $149.93 M(+6569.6%) |
| Sept 2017 | - | -$498.00 K(-113.5%) | $2.25 M(-49.3%) |
| June 2017 | - | $3.69 M(-434.2%) | $4.43 M(+446.2%) |
| Mar 2017 | - | -$1.10 M(-790.0%) | $811.00 K(-17.8%) |
| Dec 2016 | $987.00 K(-148.6%) | $160.00 K(-90.5%) | $987.00 K(+177.2%) |
| Sept 2016 | - | $1.68 M(+2271.8%) | $356.00 K(-121.2%) |
| June 2016 | - | $71.00 K(-107.7%) | -$1.68 M(-21.1%) |
| Mar 2016 | - | -$928.00 K(+97.0%) | -$2.13 M(+4.8%) |
| Dec 2015 | -$2.03 M(-100.7%) | -$471.00 K(+33.4%) | -$2.03 M(-100.7%) |
| Sept 2015 | - | -$353.00 K(-6.6%) | $284.10 M(-0.0%) |
| June 2015 | - | -$378.00 K(-54.5%) | $284.19 M(-0.0%) |
| Mar 2015 | - | -$830.00 K(-100.3%) | $284.21 M(+0.1%) |
| Dec 2014 | $283.81 M(<-9900.0%) | $285.67 M(<-9900.0%) | $283.81 M(<-9900.0%) |
| Sept 2014 | - | -$266.00 K(-26.1%) | -$1.97 M(+17.1%) |
| June 2014 | - | -$360.00 K(-70.8%) | -$1.68 M(+4.5%) |
| Mar 2014 | - | -$1.23 M(+999.1%) | -$1.61 M(+15.8%) |
| Dec 2013 | -$1.39 M(-103.8%) | -$112.00 K(-609.1%) | -$1.39 M(-103.9%) |
| Sept 2013 | - | $22.00 K(-107.6%) | $35.55 M(-1.1%) |
| June 2013 | - | -$288.00 K(-71.5%) | $35.93 M(-0.4%) |
| Mar 2013 | - | -$1.01 M(-102.7%) | $36.09 M(-0.8%) |
| Dec 2012 | $36.38 M | $36.83 M(+8947.9%) | $36.38 M(-77.2%) |
| Sept 2012 | - | $407.00 K(-415.5%) | $159.80 M(+0.5%) |
| June 2012 | - | -$129.00 K(-82.1%) | $159.07 M(+1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$722.00 K(-100.5%) | $156.59 M(-0.3%) |
| Dec 2011 | $157.08 M(+10.0%) | $160.25 M(<-9900.0%) | $157.08 M(-4681.0%) |
| Sept 2011 | - | -$328.00 K(-87.4%) | -$3.43 M(-82.3%) |
| June 2011 | - | -$2.60 M(+1022.0%) | -$19.37 M(-47.0%) |
| Mar 2011 | - | -$232.00 K(-12.8%) | -$36.54 M(-125.6%) |
| Dec 2010 | $142.87 M(+55.6%) | -$266.00 K(-98.4%) | $142.87 M(-27.7%) |
| Sept 2010 | - | -$16.27 M(-17.7%) | $197.65 M(-8.0%) |
| June 2010 | - | -$19.77 M(-111.0%) | $214.74 M(-16.3%) |
| Mar 2010 | - | $179.17 M(+228.6%) | $256.56 M(+179.4%) |
| Dec 2009 | $91.82 M(<-9900.0%) | $54.52 M(+6573.3%) | $91.82 M(+147.7%) |
| Sept 2009 | - | $817.00 K(-96.3%) | $37.07 M(+2.9%) |
| June 2009 | - | $22.05 M(+52.8%) | $36.03 M(+161.7%) |
| Mar 2009 | - | $14.43 M(-6347.2%) | $13.77 M(-1664.5%) |
| Dec 2008 | -$880.00 K(-100.3%) | -$231.00 K(+6.0%) | -$880.00 K(-14.6%) |
| Sept 2008 | - | -$218.00 K(+1.9%) | -$1.03 M(-100.5%) |
| June 2008 | - | -$214.00 K(-1.4%) | $197.04 M(-22.5%) |
| Mar 2008 | - | -$217.00 K(-43.0%) | $254.12 M(-0.3%) |
| Dec 2007 | $254.99 M(+526.5%) | -$381.00 K(-100.2%) | $254.99 M(-12.9%) |
| Sept 2007 | - | $197.85 M(+247.9%) | $292.70 M(+197.4%) |
| June 2007 | - | $56.87 M(+8716.6%) | $98.42 M(+137.6%) |
| Mar 2007 | - | $645.00 K(-98.3%) | $41.42 M(+1.8%) |
| Dec 2006 | $40.70 M(<-9900.0%) | $37.34 M(+946.7%) | $40.70 M(+1165.2%) |
| Sept 2006 | - | $3.57 M(-2802.3%) | $3.22 M(-878.9%) |
| June 2006 | - | -$132.00 K(+85.9%) | -$413.00 K(+297.1%) |
| Mar 2006 | - | -$71.00 K(-51.7%) | -$104.00 K(+9.5%) |
| Dec 2005 | -$95.00 K(-99.5%) | -$147.00 K(+133.3%) | -$95.00 K(-552.4%) |
| Sept 2005 | - | -$63.00 K(-135.6%) | $21.00 K(-520.0%) |
| June 2005 | - | $177.00 K(-385.5%) | -$5000.00(-100.0%) |
| Mar 2005 | - | -$62.00 K(+100.0%) | -$20.73 M(+6.5%) |
| Dec 2004 | -$19.47 M(-138.6%) | -$31.00 K(-65.2%) | -$19.47 M(+0.8%) |
| Sept 2004 | - | -$89.00 K(-99.6%) | -$19.32 M(-162.4%) |
| June 2004 | - | -$20.55 M(-1809.6%) | $30.97 M(-40.0%) |
| Mar 2004 | - | $1.20 M(+910.1%) | $51.58 M(+2.4%) |
| Dec 2003 | $50.40 M(+1001.8%) | $119.00 K(-99.8%) | $50.40 M(-7.3%) |
| Sept 2003 | - | $50.20 M(>+9900.0%) | $54.37 M(+1181.2%) |
| June 2003 | - | $59.00 K(+247.1%) | $4.24 M(-1.9%) |
| Mar 2003 | - | $17.00 K(-99.6%) | $4.32 M(-5.5%) |
| Dec 2002 | $4.57 M(-243.3%) | $4.09 M(+5509.6%) | $4.57 M(+1351.1%) |
| Sept 2002 | - | $73.00 K(-47.5%) | $315.20 K(-123.9%) |
| June 2002 | - | $139.00 K(-47.9%) | -$1.32 M(-54.0%) |
| Mar 2002 | - | $267.00 K(-263.0%) | -$2.87 M(-10.1%) |
| Dec 2001 | -$3.19 M(-101.6%) | -$163.80 K(-89.5%) | -$3.19 M(+7.9%) |
| Sept 2001 | - | -$1.56 M(+10.7%) | -$2.96 M(+189.6%) |
| June 2001 | - | -$1.41 M(+2441.3%) | -$1.02 M(-100.5%) |
| Mar 2001 | - | -$55.50 K(-180.9%) | $203.87 M(+0.6%) |
| Dec 2000 | $202.74 M(+5692.4%) | $68.60 K(-81.7%) | $202.73 M(+0.0%) |
| Sept 2000 | - | $375.60 K(-99.8%) | $202.67 M(+0.2%) |
| June 2000 | - | $203.48 M(<-9900.0%) | $202.29 M(<-9900.0%) |
| Mar 2000 | - | -$1.19 M | -$1.19 M |
| Dec 1999 | $3.50 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual CFF year-on-year change?
- What is Lexicon Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly CFF year-on-year change?
- What is Lexicon Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM CFF year-on-year change?
What is Lexicon Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of LXRX is $187.96 M
What is the all time high annual CFF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual cash flow from financing activities is $283.81 M
What is Lexicon Pharmaceuticals annual CFF year-on-year change?
Over the past year, LXRX annual cash flow from financing activities has changed by +$45.75 M (+32.17%)
What is Lexicon Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of LXRX is -$916.00 K
What is the all time high quarterly CFF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly cash flow from financing activities is $285.67 M
What is Lexicon Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, LXRX quarterly cash flow from financing activities has changed by -$706.00 K (-336.19%)
What is Lexicon Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of LXRX is $238.45 M
What is the all time high TTM CFF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM cash flow from financing activities is $428.17 M
What is Lexicon Pharmaceuticals TTM CFF year-on-year change?
Over the past year, LXRX TTM cash flow from financing activities has changed by +$25.59 M (+12.02%)